These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 33040281)

  • 1. A pediatric case of moderate active ulcerative colitis successfully treated with vedolizumab in Japan.
    Ikeuchi A; Kakiuchi T; Ibi A; Matsuo M
    Clin J Gastroenterol; 2021 Feb; 14(1):146-151. PubMed ID: 33040281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.
    Hernandez L; Kuwabara H; Shah A; Yamabe K; Burnett H; Fahrbach K; Koufopoulou M; Iwakiri R
    Pharmacoeconomics; 2020 Jan; 38(1):69-84. PubMed ID: 31552601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Essat M; Tappenden P; Ren S; Bessey A; Archer R; Wong R; Lobo A; Hoque S
    Pharmacoeconomics; 2016 Mar; 34(3):245-57. PubMed ID: 26477040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pediatric case of infliximab-resistant ulcerative colitis successfully treated using vedolizumab.
    Fukura S; Takei M; Takeuchi S; Tayama T; Ono A; Ichihara Y; Shichijo K; Suzuki Y; Mori K; Kondo S
    J Med Invest; 2023; 70(1.2):294-297. PubMed ID: 37164738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease.
    Singh N; Rabizadeh S; Jossen J; Pittman N; Check M; Hashemi G; Phan BL; Hyams JS; Dubinsky MC
    Inflamm Bowel Dis; 2016 Sep; 22(9):2121-6. PubMed ID: 27542130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety of vedolizumab for the treatment of ulcerative colitis.
    Novak G; Hindryckx P; Khanna R; Jairath V; Feagan BG
    Expert Opin Drug Saf; 2017 Apr; 16(4):501-507. PubMed ID: 28276855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness Analysis of Vedolizumab Compared With Infliximab in Anti-TNF-α-Naïve Patients With Moderate-to-Severe Ulcerative Colitis in China.
    Zhou T; Sheng Y; Guan H; Meng R; Wang Z
    Front Public Health; 2021; 9():704889. PubMed ID: 34490187
    [No Abstract]   [Full Text] [Related]  

  • 8. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis.
    Scott FI; Luo M; Shah Y; Lasch K; Vajravelu RK; Mamtani R; Fennimore B; Gerich ME; Lewis JD
    J Crohns Colitis; 2020 Jun; 14(5):575-587. PubMed ID: 31901085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists.
    Feagan BG; Rubin DT; Danese S; Vermeire S; Abhyankar B; Sankoh S; James A; Smyth M
    Clin Gastroenterol Hepatol; 2017 Feb; 15(2):229-239.e5. PubMed ID: 27639327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of antitumour necrosis factor agents and vedolizumab in ulcerative colitis.
    Davis R; McParland P; Dodd S; Storey D; Probert C; Collins P; Skouras T; Steel A; Derbyshire E; Dibb M; Subramanian S
    Eur J Gastroenterol Hepatol; 2019 Jun; 31(6):661-667. PubMed ID: 30855421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the Optimal Position for Vedolizumab in the Treatment of Ulcerative Colitis: A Simulation Model.
    Scott FI; Shah Y; Lasch K; Luo M; Lewis JD
    Inflamm Bowel Dis; 2018 Jan; 24(2):286-295. PubMed ID: 29361100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study.
    Motoya S; Watanabe K; Ogata H; Kanai T; Matsui T; Suzuki Y; Shikamura M; Sugiura K; Oda K; Hori T; Araki T; Watanabe M; Hibi T
    PLoS One; 2019; 14(2):e0212989. PubMed ID: 30807613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Vedolizumab in Patients With Refractory Ulcerative Colitis.
    Pellet G; Stefanescu C; Carbonnel F; Peyrin-Biroulet L; Roblin X; Allimant C; Nachury M; Nancey S; Filippi J; Altwegg R; Brixi H; Fotsing G; de Rosamel L; Shili S; Laharie D;
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):494-501. PubMed ID: 30213584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study.
    Kim JY; Zaghiyan K; Lightner A; Fleshner P
    BMC Surg; 2020 Mar; 20(1):46. PubMed ID: 32138717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis.
    Battat R; Ma C; Jairath V; Khanna R; Feagan BG
    Drug Saf; 2019 May; 42(5):617-632. PubMed ID: 30830573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis.
    Dignass AU; Siegmund B; Goertz R; Schneidewind G; Fanter L
    Scand J Gastroenterol; 2019 Feb; 54(2):178-187. PubMed ID: 30735443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease.
    Schneider AM; Weghuber D; Hetzer B; Entenmann A; Müller T; Zimmermann G; Schütz S; Huber WD; Pichler J
    BMC Gastroenterol; 2018 Sep; 18(1):140. PubMed ID: 30219028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
    McLean LP; Cross RK
    Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Week 2 Symptomatic Response with Vedolizumab as a Predictive Factor in Japanese Anti-TNFα-Naive Patients with Ulcerative Colitis: A post hoc Analysis of a Randomized, Placebo-Controlled Phase 3 Trial.
    Nagahori M; Watanabe K; Motoya S; Ogata H; Kanai T; Matsui T; Suzuki Y; Pinton P; Ursos L; Sakamoto S; Shikamura M; Hori T; Fernandez J; Hibi T; Watanabe M
    Digestion; 2021; 102(5):742-752. PubMed ID: 33454706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current position on Vedolizumab for ulcerative colitis and Crohn's disease].
    Schreiber S; Dignass AU; Hartmann H; Kruis W; Rogler G; Siegmund B; Stallmach A; Witte C; Bokemeyer B
    Z Gastroenterol; 2015 Jun; 53(6):591-602. PubMed ID: 26016456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.